The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV

NCT02116257 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

108

Enrollment

OTHER

Sponsor class

Conditions

PONV
Propacetamol

Interventions

DRUG: Propacetamol
DRUG: PCA regimen

Sponsor

Yonsei University